In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Pfizer licenses neratinib to newly created Puma Biotechnology

Executive Summary

Cancer-focused start-up Puma Biotechnology Inc. has picked up its first compound by licensing worldwide development and commercialization rights to Pfizer Inc.’s neratinib, a Phase III tyrosine kinase inhibitor for HER2-positive breast cancer.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Reverse Licensing
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register